EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oncogenic IDH1 mut drives robust loss of histone acetylation and increases chromatin heterogeneity

Noa Furth iD, Niv Cohen, Avishay Spitzer, Tomer-Meir Salame, Bareket Dassa, Tevie Mehlman, Alexander Brandis iD, Arieh Moussaieff iD, Dinorah Friedmann-Morvinski iD, Maria G Castro iD, Jerome Fortin, Mario L Suvà iD und 4 weitere

Proceedings of the National Academy of Sciences · 07.01.2025 · 122 (1)

DOI: 10.1073/pnas.2403862122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 30.12.2024. Verfasst von Noa Furth und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Histones, Glioma, Mutation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EC | European Research Council (ERC), The Israeli Science Foundation, Emerson Collective (Emerson).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2 mut ) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype. Yet, the complete depiction of the epigenetic alterations in IDH mut cells has not been thoroughly explored. Here, we applied an unbiased approach, leveraging epigenetic-focused cytometry by time-of-flight (CyTOF) analysis, to systematically profile the effect of mutant-IDH1 expression on a broad panel of histone modifications at single-cell resolution. This analysis revealed extensive remodeling of chromatin patterns by mutant-IDH1, with the most prominent being deregulation of histone acetylation marks. The loss of histone acetylation occurs rapidly following mutant-IDH1 induction and affects acetylation patterns over enhancers and intergenic regions. Notably, the changes in acetylation are not predominantly driven by 2-HG, can be rescued by pharmacological inhibition of mutant-IDH1, and reversed by acetate supplementations. Furthermore, cells expressing mutant-IDH1 show higher epigenetic and transcriptional heterogeneity and upregulation of oncogenes such as KRAS and MYC, highlighting its tumorigenic potential. Our study underscores the tight interaction between chromatin and metabolism dysregulation in glioma and highlights epigenetic and oncogenic pathways affected by mutant-IDH1-driven metabolic rewiring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseHistonesGliomaMutationChromatinHumansAcetylationCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticGlutaratesBrain Neoplasms

Stichwörter der Autor:innen

CyTOFchromatinepigeneticsmutant-IDH1oncometabolite

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanHistonesChromatinGlutaratesalpha-hydroxyglutarate

Autor:innen und Institutionen

  • Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Mass Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Bioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot 7610001, Israel.

ORCID-Profile: Noa Furth, Alexander Brandis, Arieh Moussaieff, Dinorah Friedmann-Morvinski, Maria G Castro, Mario L Suvà, Ayelet Erez, Guy Ron, Efrat Shema

Förderung

  • EC | European Research Council (ERC)
  • The Israeli Science Foundation
  • Emerson Collective (Emerson)
  • The Israel Cancer Research Fund
  • Minerva Foundation (Minerva Stiftung)
  • Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics
  • Lisa and Jeffrey Aronin Family Career Development chair

Zitieren

APA

Furth, N., Cohen, N., Spitzer, A., Salame, T. M., Dassa, B., Mehlman, T., Brandis, A., Moussaieff, A., Friedmann-Morvinski, D., Castro, M. G., Fortin, J., Suvà, M. L., Tirosh, I., Erez, A., Ron, G., & Shema, E. (2025). Oncogenic IDH1 mut drives robust loss of histone acetylation and increases chromatin heterogeneity. Proceedings of the National Academy of Sciences, 122(1). https://doi.org/10.1073/pnas.2403862122

Vancouver

Furth N, Cohen N, Spitzer A, Salame TM, Dassa B, Mehlman T, et al. Oncogenic IDH1 mut drives robust loss of histone acetylation and increases chromatin heterogeneity. Proceedings of the National Academy of Sciences. 2025;122(1). doi:10.1073/pnas.2403862122

BibTeX
@article{Furth2025,
  author = {Furth, Noa and Cohen, Niv and Spitzer, Avishay and Salame, Tomer-Meir and Dassa, Bareket and Mehlman, Tevie and Brandis, Alexander and Moussaieff, Arieh and Friedmann-Morvinski, Dinorah and Castro, Maria G and Fortin, Jerome and Suvà, Mario L and Tirosh, Itay and Erez, Ayelet and Ron, Guy and Shema, Efrat},
  title = {Oncogenic IDH1 mut drives robust loss of histone acetylation and increases chromatin heterogeneity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {1},
  doi = {10.1073/pnas.2403862122}
}
Kostenlos starten →